5,406
edits
Line 100: | Line 100: | ||
=The future of high pressure homogenizers= | |||
In 2010, the FDA announced a recall of eleven batches of clevidipine butyrate injection emulsion across the United States due to the possibility that the emulsion contained inert metallic particles.4 Particles gathering and forming larger particles would theoretically lead to clogging in blood capillaries, causing mechanical damage to the body or other acute or chronic inflammations. | |||
Therefore, it is not recommended to use the impact type of homogenization chamber in the pharmaceutical industry. These models are no longer suitable for mass production of pharmaceutical emulsion injection. The interaction mechanism is also more durable in ultra-high pressure machines when equipped with temperature control. With increasing demand for nanomaterials, which require higher pressure and higher performance in nano-dispersion, interaction chambers will be more widely used in nanotechnology fields, such as pharmaceuticals, semiconductors, and microelectronics. | |||
In the past century, the homogenizer has experienced many changes, from the shift from low pressure (10,000 psi) to high (20,000 psi) and ultra-high pressure (60,000 psi); from the homogenizing valve design, to the use of interaction chambers and chambers with temperature control; from the direct-drive type to the intensifier and multi-pump constant pressure types. | |||
With the development of the high thrust linear actuator system, high-thrust and low-speed linear motors will be applied in ultra-high pressure homogenizers in the future. As the pressure increases, temperature control will be a major technical challenge—and therefore, a temperature-controlled and ultra-high pressure-durable interaction chamber is a major avenue for future development. | |||
edits